At the Pistoia Alliance we believe in transparency and accountability. When it comes to decision-making processes, documentation, and project output, we share as much as we can via the channels below. Members can gain access to members-only resources upon request.
Google Drive - Documents
Project and operational documents are stored in our Google Drive. There are separate public, private, and members-only areas.
Confluence - Wiki
We maintain a wiki for meeting minutes, discussions, policies, and other dynamic documents. There are separate public, private, and members-only areas.
IP3 - New Ideas
Browse the current selection of ideas and join in the debate, or contribute new ideas of your own. Everyone can join the conversation.
Each of our projects publishes key information and output on this website. Browse all our projects, past and present, on the projects page.
Read All About It
Our public wiki hosts a bibliography page containing a list of all our publications, articles, and substantial media mentions.
Put Us In Your Diary
Our events page contains the dates of all our major events, conferences, webinars, AGMs, and key meetings.
Pistoia Alliance Debates
Catch up at your leisure with webinar recordings of our past debates, or read about and register for the next one in the series.
Where permission is granted, all presentations from our public webinars and conferences are uploaded to SlideShare. Browse the collection online.
Read about all our activities in our regular newsletter: Innovation in Action
Our latest blog posts
The recording from the "Real World Data / Real World Evidence" Pistoia Alliance Debates webinar held on Tuesday 6th June 2017 is available here.
We are pleased to announce the outline agenda for our 2017 US Conference. If you'd like to attend, please register now!
Since August 2016 the Pistoia Alliance has welcomed several companies and individuals as new members.
The Pistoia Alliance Advisory Board met on Wednesday 29th March. Steve Arlington, President of the Pistoia Alliance, invited its members to consider the biopharma and healthcare landscape as it might be in 2030.